MVC

Mitral Valve Complex (MVC) disease, more formally known as Myxomatous Mitral Valve Disease (MMVD), is the most common acquired heart condition in dogs, accounting for approximately 75 percent of all canine cardiac disease seen in veterinary practice. The condition involves progressive degeneration of the mitral valve, the valve that separates the left atrium from the left ventricle, leading to improper valve closure and backward leakage of blood during each heartbeat.

The mitral valve complex is not simply the valve leaflets themselves but includes the valve annulus (the ring of fibrous tissue supporting the valve), the chordae tendineae (the thin cords connecting the leaflets to the papillary muscles), and the papillary muscles that anchor the apparatus to the ventricular wall. In MVC, myxomatous degeneration causes progressive thickening, distortion, and weakening of these components, disrupting the precisely coordinated mechanism that normally ensures a tight seal during ventricular contraction.

As the valve degenerates, it fails to close completely during systole, allowing blood to flow backward from the left ventricle into the left atrium. This backward flow is called mitral regurgitation and produces the characteristic heart murmur that is often the first clinical sign detected during routine veterinary examination. Initially, the volume of regurgitant blood is small and the heart compensates effectively, but as the valve deterioration progresses over months to years, the volume of regurgitation increases and the heart's compensatory mechanisms become overwhelmed.

MVC is overwhelmingly a disease of older, small-breed dogs, though it can affect dogs of any size, breed, or age. The disease has a prolonged preclinical phase during which the dog has detectable valve disease but no clinical symptoms. Many dogs live for years with a heart murmur before progressing to the symptomatic stage, and some never develop clinical signs at all. Understanding the natural progression of the disease is essential for appropriate monitoring and timely intervention.

The clinical presentation of MVC follows a predictable pattern that corresponds to the progressive stages of the disease. In the early stages, most dogs are completely asymptomatic, and the disease is discovered incidentally when a veterinarian detects a heart murmur during a routine physical examination. The murmur is typically a systolic murmur heard best over the left apex of the heart and is graded on a scale of one to six based on its intensity.

As mitral regurgitation worsens, the left atrium enlarges to accommodate the increasing volume of blood flowing backward through the incompetent valve. Left atrial enlargement can compress the left mainstem bronchus, causing a persistent cough that is often the first symptom owners notice. This cough is typically dry and nonproductive, may be more pronounced at night or during excitement, and can be mistaken for kennel cough or tracheal collapse, both of which are also common in the small breeds predisposed to MVC.

When the heart's compensatory mechanisms are exhausted, the dog develops congestive heart failure (CHF), which represents a critical turning point in the disease. Left-sided CHF causes fluid to accumulate in the lungs (pulmonary edema), producing symptoms of respiratory distress including increased respiratory rate and effort, open-mouth breathing, reluctance to lie down, exercise intolerance, and cyanosis (bluish discoloration of the gums). Dogs in acute CHF may present as emergencies with severe respiratory distress and require immediate stabilization.

Additional symptoms that may develop as the disease progresses include fatigue, reduced willingness to exercise or play, syncope (fainting episodes) particularly during excitement or exertion, restlessness at night, decreased appetite, and weight loss or muscle wasting. Some dogs develop abdominal distension due to ascites (fluid accumulation in the abdominal cavity) if right-sided heart failure develops secondary to pulmonary hypertension. The development of cardiac arrhythmias, particularly atrial fibrillation in dogs with severely enlarged left atria, can cause sudden worsening of symptoms.

Owners of breeds predisposed to MVC should be aware of the subtle early signs that may indicate disease progression, including mild exercise intolerance, increased sleeping, and occasional coughing. Early recognition of these signs allows for timely veterinary evaluation and potential initiation of therapy that may slow disease progression.

The fundamental cause of MVC is myxomatous degeneration of the mitral valve apparatus, a process in which the normal strong, thin, translucent valve tissue is progressively replaced by weakened, thickened, opaque tissue containing excessive accumulations of glycosaminoglycans and proteoglycans within the valve matrix. This degenerative process disrupts the structural integrity of the valve leaflets, causing them to become thickened, nodular, and eventually prolapsing into the left atrium during ventricular contraction.

The exact mechanisms initiating myxomatous degeneration remain incompletely understood, but research has identified several contributing factors. At the cellular level, the valve interstitial cells that normally maintain the extracellular matrix of the valve undergo phenotypic changes, transitioning from quiescent fibroblast-like cells to activated myofibroblasts. These activated cells produce abnormal extracellular matrix components and release enzymes, including matrix metalloproteinases, that degrade the normal collagen and elastin framework of the valve.

Genetic factors play a significant role in the development of MVC, as evidenced by the strong breed predisposition and the heritability of the disease demonstrated in breeding studies. Research in Cavalier King Charles Spaniels has shown that the age of onset and rate of progression are heritable traits, and ongoing genome-wide association studies are working to identify the specific genes involved. The inheritance pattern appears to be polygenic, meaning multiple genes contribute to disease susceptibility.

The hemodynamic consequences of progressive mitral regurgitation drive the clinical manifestations of the disease. As the volume of blood leaking backward through the mitral valve increases, the left atrium dilates to accommodate the extra volume, and the left ventricle must pump a larger total stroke volume to maintain adequate forward cardiac output. This volume overload causes eccentric hypertrophy of the left ventricle, in which the chamber dilates and the wall thickness remains relatively preserved. Initially, these compensatory changes are adaptive and maintain cardiac output, but eventually the myocardium becomes dysfunctional and heart failure develops.

Neurohormonal activation is a critical component of the disease's pathophysiology. The renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system are activated in response to decreased effective circulating volume, leading to sodium and water retention, vasoconstriction, and cardiac remodeling. While these neurohormonal responses are initially compensatory, chronic activation contributes to progressive cardiac dysfunction, fluid overload, and the development of congestive heart failure.

Diagnosis of MVC typically begins with the detection of a left apical systolic heart murmur during routine veterinary examination. While the presence of a murmur in a predisposed breed is highly suggestive of MVC, a comprehensive diagnostic workup is necessary to confirm the diagnosis, assess disease severity, and establish the appropriate stage for treatment planning.

Echocardiography (cardiac ultrasound) is the cornerstone of MVC diagnosis and staging. This non-invasive imaging modality allows direct visualization of the mitral valve apparatus, assessment of valve morphology, quantification of mitral regurgitation severity, and measurement of cardiac chamber dimensions. Key echocardiographic findings in MVC include thickened and prolapsing mitral valve leaflets, a regurgitant jet visible on color-flow Doppler, left atrial dilation, and left ventricular dilation with preserved or increased fractional shortening in the compensated stage.

The ACVIM (American College of Veterinary Internal Medicine) staging system provides a standardized framework for classifying disease severity and guiding treatment decisions. Stage A includes dogs at high risk for developing MVC but with no current murmur or structural changes, such as young Cavalier King Charles Spaniels. Stage B encompasses dogs with a murmur and valve changes but no clinical signs, subdivided into B1 (no significant cardiac remodeling) and B2 (significant left atrial and ventricular enlargement). Stage C includes dogs with current or previous clinical signs of heart failure, and Stage D describes dogs with refractory heart failure that is not adequately controlled with standard therapy.

Thoracic radiographs complement echocardiography by providing information about cardiac silhouette size, pulmonary vascular patterns, and the presence or absence of pulmonary edema or pleural effusion. Radiographic findings that support MVC diagnosis include left atrial enlargement visible as straightening of the caudal cardiac border and dorsal displacement of the trachea and mainstem bronchi. In dogs with CHF, diffuse or perihilar pulmonary infiltrates consistent with pulmonary edema are typically present.

Additional diagnostic tests may include electrocardiography to detect cardiac arrhythmias, blood pressure measurement, and cardiac biomarker testing. Cardiac troponin I and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are blood-based biomarkers that can provide supplementary information about myocardial injury and cardiac wall stress, respectively. These biomarkers can be particularly useful for monitoring disease progression and predicting the onset of heart failure in dogs with preclinical disease.

The treatment approach for MVC is determined by the disease stage, and current guidelines are based on the landmark EPIC (Evaluation of Pimobendan In dogs with Cardiomegaly) trial and other major clinical studies. Treatment recommendations have evolved significantly in recent years, with clear evidence now supporting early intervention in dogs with preclinical disease that has progressed to cause significant cardiac enlargement.

Dogs in Stage B1, with a murmur but no significant cardiac remodeling, do not currently require medical therapy. Regular monitoring with annual or semi-annual echocardiography and radiography is recommended to detect progression to Stage B2. Owners should be educated about the signs of disease progression and heart failure so they can seek prompt veterinary attention if symptoms develop.

Dogs in Stage B2, with significant left atrial and ventricular enlargement but no clinical signs of heart failure, benefit from treatment with pimobendan, an inodilator that improves cardiac contractility and reduces cardiac workload. The EPIC trial demonstrated that pimobendan delayed the onset of heart failure by approximately 15 months in Stage B2 dogs compared to placebo. Pimobendan is administered orally at a dose of 0.25 to 0.3 milligrams per kilogram divided into two daily doses.

Dogs in Stage C, with current or previous signs of congestive heart failure, require a more comprehensive medical regimen. The standard treatment protocol includes pimobendan, furosemide (a loop diuretic to remove excess fluid), and an angiotensin-converting enzyme (ACE) inhibitor such as enalapril or benazepril. Furosemide dosing is titrated to the minimum effective dose that controls fluid accumulation while minimizing the risk of dehydration and electrolyte imbalances. Spironolactone, an aldosterone antagonist, may be added to provide additional neurohormonal modulation and potassium-sparing diuretic effects.

Stage D patients with refractory heart failure require escalation of therapy, which may include increasing furosemide doses, adding a second diuretic such as hydrochlorothiazide, adjusting pimobendan dosing, managing arrhythmias with antiarrhythmic drugs, and considering sildenafil for dogs with pulmonary hypertension. These patients require frequent monitoring and dose adjustments to maintain stability. Dietary sodium restriction and caloric support are important adjuncts to medical therapy in heart failure patients.

Mitral valve repair surgery has emerged as a potentially curative treatment option for dogs with MVC, representing a significant advancement in veterinary cardiac care. The procedure involves open-heart surgery performed on cardiopulmonary bypass, during which the surgeon repairs the diseased mitral valve to restore competent valve function and eliminate or significantly reduce mitral regurgitation.

The surgical technique most commonly performed in dogs involves a combination of chordal replacement and annuloplasty. Ruptured or elongated chordae tendineae are replaced with expanded polytetrafluoroethylene (ePTFE) sutures, which are secured to the papillary muscles and the free edge of the valve leaflets to restore proper leaflet coaptation. An annuloplasty is performed to reduce the dilated mitral valve annulus to its normal dimensions, typically using a series of pledgeted sutures to plicate the annulus rather than implanting a prosthetic ring.

Mitral valve repair surgery in dogs was pioneered in Japan and has been performed at specialized centers around the world with increasingly favorable outcomes. When performed by experienced surgical teams, the procedure has reported success rates exceeding 90 percent, with many dogs achieving dramatic improvement in cardiac function and returning to normal activity levels. Successful repair effectively eliminates the hemodynamic burden of mitral regurgitation and can allow discontinuation of most or all cardiac medications postoperatively.

Despite its potential for cure, mitral valve repair surgery is not appropriate for all dogs with MVC. Ideal surgical candidates are dogs in Stage C or early Stage D that have preserved left ventricular function and are otherwise healthy enough to tolerate general anesthesia and cardiopulmonary bypass. Dogs with severely impaired ventricular function, significant comorbidities, or extreme age may not be suitable candidates. The procedure also requires access to a specialized facility with the necessary equipment and a surgical team experienced in canine open-heart surgery, which limits availability.

The cost of mitral valve repair surgery is substantial, often ranging from $30,000 to $50,000 or more depending on the facility and geographic location. This financial consideration, combined with geographic limitations in access to qualified surgical centers, means that medical management remains the standard of care for the majority of dogs with MVC. However, as surgical techniques continue to improve and more centers develop the capability to perform the procedure, surgical repair is becoming an increasingly viable option for appropriate candidates.

MVC demonstrates one of the strongest breed predispositions of any canine disease, with small and toy breeds being disproportionately affected compared to medium and large breeds. The Cavalier King Charles Spaniel stands apart as the breed most severely affected by MVC, with studies showing that virtually 100 percent of Cavaliers will develop some degree of mitral valve degeneration if they live long enough. More critically, Cavaliers tend to develop the disease at a much younger age than other breeds, with murmurs detectable as early as one to two years of age in some individuals.

Dachshunds represent another highly predisposed breed, with studies demonstrating a prevalence of MVC exceeding 40 percent in older individuals. The disease in Dachshunds tends to follow a similar progressive pattern to other small breeds, with initial murmur detection in middle age followed by gradual progression over several years. Miniature and Toy Poodles are also commonly affected, with prevalence rates increasing significantly after seven to eight years of age.

Chihuahuas, Yorkshire Terriers, Maltese, Pomeranians, and Shih Tzus are among the other small breeds with documented high prevalence of MVC. In these breeds, the disease is considered an almost expected consequence of aging, though the rate of progression to clinically significant disease varies considerably among individuals. Some dogs maintain stable, mild mitral regurgitation for years without progressing to heart failure, while others experience rapid deterioration.

Cocker Spaniels and Miniature Schnauzers occupy an interesting position as medium-sized breeds with notable MVC prevalence. Large-breed dogs can also develop myxomatous valve disease, though it is less common and tends to present differently, with Dalmatians, Bull Terriers, and German Shepherds occasionally affected. In large breeds, tricuspid valve involvement is more frequently seen alongside mitral disease.

The strong breed predisposition has led to breed-specific screening programs, particularly for Cavalier King Charles Spaniels. The Mitral Valve Disease Breeding Protocol recommends that Cavaliers not be bred before age two and a half years and only if they and their parents are free of murmurs. Similar screening recommendations exist for other predisposed breeds. Responsible breeding practices informed by cardiac screening represent the most effective long-term strategy for reducing the prevalence and severity of MVC in susceptible breeds.

Living with a dog diagnosed with MVC requires ongoing vigilance, consistent medication administration, and close collaboration with the veterinary care team. The chronic and progressive nature of the disease means that management is a long-term commitment, and owners play a critical role in monitoring their dog's condition, recognizing early signs of deterioration, and maintaining the therapeutic regimen.

Home monitoring of resting respiratory rate (RRR) is one of the most valuable tools available to owners of dogs with MVC. The resting respiratory rate is counted while the dog is sleeping or calmly resting by observing chest movements for 30 seconds and multiplying by two. Normal resting respiratory rates in dogs are typically below 30 breaths per minute. An increase in resting respiratory rate above the dog's baseline, particularly above 40 breaths per minute, is often the earliest detectable sign of developing pulmonary edema and impending heart failure. Owners should establish their dog's baseline RRR and check it regularly, reporting any sustained increases to their veterinarian promptly.

Dietary management for dogs with MVC focuses on adequate nutrition while avoiding excessive sodium intake. While severe sodium restriction is no longer recommended in the early stages of disease, moderate sodium restriction is appropriate for dogs in heart failure. Maintaining adequate caloric intake and lean body mass is important, as cardiac cachexia (muscle wasting associated with chronic heart failure) is a common complication that negatively impacts quality of life and survival. Commercial cardiac diets are available and may be appropriate for some patients, though consultation with the veterinarian is recommended before making dietary changes.

Exercise management should be tailored to the individual dog's disease stage and functional capacity. Dogs in the preclinical stages of MVC can typically maintain normal exercise routines without restriction. As the disease progresses and heart failure develops, exercise tolerance decreases and activity should be adjusted accordingly. Dogs should never be forced to exercise beyond their comfort level, and owners should watch for signs of excessive fatigue, labored breathing, or collapse during activity. Moderate, regular exercise at a comfortable pace is generally preferable to vigorous, sporadic activity.

Medication administration requires consistency and attention to detail. Pimobendan must be given on an empty stomach, ideally one hour before meals, to ensure adequate absorption. Diuretics like furosemide should be given at consistent times each day, and owners should be aware that increased urination is an expected effect. Keeping a medication log can help ensure doses are not missed, and having an adequate supply of all medications prevents dangerous interruptions in therapy.

Several important complications can arise during the course of MVC, each requiring specific recognition and management. Understanding these potential complications helps owners and veterinarians anticipate problems and respond appropriately when they occur.

Chordal rupture is a significant complication that can cause acute worsening of mitral regurgitation. The chordae tendineae, which are already weakened by myxomatous degeneration, are under continuous mechanical stress from the forces generated during ventricular contraction. When a major chorda ruptures, the valve leaflet it was supporting loses its tethering and flails into the left atrium, dramatically increasing the volume of regurgitant blood. This can precipitate acute, severe heart failure in a dog that was previously stable, requiring emergency intervention with aggressive diuretic therapy and potentially intensive care.

Atrial fibrillation is the most clinically significant arrhythmia associated with MVC and typically develops in dogs with severe left atrial enlargement. The dilated atrium provides the substrate for this chaotic electrical rhythm, which causes loss of coordinated atrial contraction and often results in a rapid ventricular rate. Atrial fibrillation can significantly worsen heart failure symptoms and may require treatment with rate-control medications such as diltiazem or digoxin. The development of atrial fibrillation generally indicates advanced disease and carries a worse prognosis.

Pulmonary hypertension (PH) can develop secondary to chronic elevation of left atrial pressure and pulmonary venous congestion. As pulmonary arterial pressures rise, the right ventricle must work harder to pump blood through the lungs, eventually leading to right-sided heart failure with signs such as ascites, jugular venous distension, and hepatomegaly. Pulmonary hypertension is detected by echocardiography and may be treated with sildenafil, a phosphodiesterase-5 inhibitor that reduces pulmonary arterial pressure.

Left atrial tear is a dramatic and often fatal complication of severe MVC in which the thin, stretched wall of the massively enlarged left atrium ruptures, usually at the junction with the pulmonary veins. The resulting hemorrhage into the pericardial sac causes cardiac tamponade, with acute collapse, pale mucous membranes, and weak pulses. Emergency pericardiocentesis (drainage of blood from around the heart) may provide temporary stabilization, but the prognosis for this complication is extremely poor.

Syncope, or fainting, occurs in some dogs with MVC and can result from multiple mechanisms including arrhythmias, sudden decreases in cardiac output during coughing fits, pulmonary hypertension, and rarely, vasovagal reflexes. Episodes are typically brief, with the dog collapsing and recovering within seconds to minutes. While individual syncopal episodes are usually not immediately dangerous, recurrent syncope warrants thorough investigation and management adjustment.

Research into MVC continues to advance on multiple fronts, with ongoing investigations into the genetic basis of the disease, novel pharmacological therapies, refinement of surgical techniques, and the development of improved monitoring tools. These research efforts hold promise for better prevention, earlier detection, and more effective treatment of this common canine cardiac condition.

Genetic research represents one of the most active areas of investigation. Genome-wide association studies and whole-genome sequencing projects are being conducted in multiple predisposed breeds with the goal of identifying the specific genetic variants that contribute to disease susceptibility and progression. In Cavalier King Charles Spaniels, several chromosomal regions of interest have been identified, though the specific causative mutations remain elusive due to the polygenic nature of the trait. Identifying genetic markers would enable genetic testing for disease risk and inform breeding decisions aimed at reducing disease prevalence.

Novel pharmacological approaches are being explored to slow or halt the progression of myxomatous valve degeneration at the tissue level. Research into the cellular and molecular mechanisms of valve degeneration has identified potential therapeutic targets, including matrix metalloproteinase inhibitors, transforming growth factor-beta pathway modulators, and serotonin receptor antagonists. Studies of the role of serotonin signaling in valve degeneration have been particularly intriguing, as they suggest a potential link between serotonin metabolism and the development of myxomatous changes.

Advances in surgical mitral valve repair continue to improve outcomes and expand access to this potentially curative treatment. Minimally invasive approaches, including transcatheter mitral valve repair techniques adapted from human interventional cardiology, are being investigated as less invasive alternatives to open-heart surgery. These catheter-based approaches, which include edge-to-edge repair devices and chordal implantation systems, could potentially make valve repair accessible to a broader population of dogs at lower cost and risk.

Telemedicine and remote monitoring technologies are being developed to improve the management of dogs with MVC. Wearable devices that continuously monitor heart rate, respiratory rate, and activity levels could provide real-time data to veterinarians, enabling earlier detection of disease progression or decompensation. Smartphone applications that guide owners in measuring resting respiratory rates and tracking trends over time are already available and represent a simple but effective tool for home monitoring. The integration of artificial intelligence and machine learning into echocardiographic analysis may also improve diagnostic accuracy and standardize disease staging across veterinary practices.